For most of the past two decades, treating erectile dysfunction (ED) meant taking a pill and timing intimacy around it. That model is changing. Daily tadalafil 5mg has emerged as a clinically validated approach that removes the planning window entirely, and recent research suggests the benefits extend well beyond the bedroom. Here is what the evidence shows.
What Is Daily Tadalafil 5mg and How Does It Work?
Tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor, a class of medications that works by blocking the enzyme responsible for breaking down cyclic guanosine monophosphate (cGMP) in penile tissue. Elevated cGMP levels allow smooth muscle to relax and blood vessels to dilate, increasing blood flow in response to sexual stimulation.
Unlike on-demand dosing, where a higher dose (10–20mg) is taken 30–60 minutes before anticipated activity, the daily 5mg protocol maintains a steady-state plasma concentration throughout the day. This means the pharmacological support is always present, and no dose timing is required before sexual activity.
Tadalafil's half-life of approximately 17.5 hours makes it uniquely suited to once-daily dosing. No other approved PDE5 inhibitor maintains meaningful plasma levels long enough to support a continuous dosing strategy with such a low milligram load.
What Clinical Research Shows About Daily Tadalafil
The clinical evidence for daily tadalafil 5mg is substantial and spans multiple study designs.
A 2024 comparative placebo-controlled study published in International Urology and Nephrology by Motawi et al. evaluated tadalafil 5mg daily across different delivery formats, including standard tablets and oral dispersible film, in men with mild-to-moderate ED. Researchers found consistent improvements in International Index of Erectile Function (IIEF) scores across delivery types, with the daily regimen demonstrating a favorable safety profile and strong patient-reported satisfaction scores.[1]
In practice, one of the major advantages of daily tadalafil is that it removes the timing burden built into on-demand dosing. That lifestyle fit is one reason many men prefer once-daily treatment when they have sex frequently enough for planning around a pill to feel intrusive.[4]
Perhaps most striking is a large 2024 study published in The American Journal of Medicine examining real-world outcomes in over 400,000 men with ED. Researchers found that tadalafil use was associated with a 34% reduction in all-cause mortality (risk ratio 0.66), a 27% reduction in myocardial infarction risk, a 34% reduction in stroke risk, and a 32% reduction in dementia risk compared to men with ED who did not use PDE5 inhibitors.[2] A parallel study by Kloner et al. published in Clinical Cardiology (2024) confirmed this association, linking tadalafil exposure to significantly lower rates of major adverse cardiovascular events (MACE).[3]
These are observational data, and causation cannot be claimed. But the signal is consistent across multiple large cohorts: daily PDE5 inhibitor use may support systemic vascular health in ways that go beyond erectile function.
Why Delivery Format Matters: Chewable and Dispersible Options
Standard oral tablets must be swallowed, absorbed through the gastrointestinal tract, and processed by hepatic first-pass metabolism before reaching systemic circulation. Chewable and sublingual formulations can bypass a portion of this pathway, allowing some absorption to begin through the oral mucosa, the tissue lining the inside of the mouth.
Alternative oral formats may matter too. Motawi et al. showed that tadalafil oral dispersible film performed comparably to standard tablets in mild-to-moderate ED, supporting the narrower point that daily tadalafil does not have to be limited to a conventional swallowed tablet.[1]
For men who have difficulty swallowing tablets, or who prefer a more convenient administration route, chewable or dispersible formulations can be clinically reasonable options when prescribed appropriately.[1,4]
Combining Tadalafil with Vardenafil: The Dual-Mechanism Approach
Tadalafil and vardenafil are both PDE5 inhibitors, but they are not identical molecules. They differ in selectivity profiles, onset characteristics, and tissue distribution. Vardenafil has a higher in-vitro potency against PDE5 (lower IC50) and a faster onset, typically 15–30 minutes versus tadalafil's 30–60 minutes.
Some clinicians have explored combining low doses of both agents to leverage complementary pharmacokinetic profiles, tadalafil providing sustained baseline support while vardenafil contributes a faster, more acute effect when needed. This approach is not FDA-approved as a fixed combination, which is why physician oversight is essential. Compounding pharmacies operating under state pharmacy board licensure and FDA-registered status can formulate such combinations under physician prescription.
OnyxMD's EPIQ CHEWS pairs Tadalafil 5mg with Vardenafil 5mg in a daily chewable format, along with Vitamin D3 and K2. The inclusion of D3 and K2 is clinically relevant: low testosterone and suboptimal vitamin D status are independently associated with ED, and K2 plays a role in calcium metabolism and arterial flexibility. This is a physician-formulated product, not a supplement stack.
Who Is a Candidate for Daily Tadalafil?
Daily tadalafil 5mg is generally well-tolerated and is FDA-approved for daily use in erectile dysfunction. It's typically considered for men who:
- Have sexual activity two or more times per week
- Find on-demand dosing inconvenient or anxiety-provoking
- Experience insufficient response from on-demand dosing due to absorption timing
- Have comorbid benign prostatic hyperplasia (BPH), for which tadalafil carries a separate FDA indication
- Prefer to remove medication timing from the sexual experience entirely
It is contraindicated in men using nitrate medications (including nitroglycerin or recreational "poppers"), certain antifungals, and some HIV protease inhibitors. A physician evaluation is required before starting any PDE5 inhibitor regimen. That evaluation is not optional, it's the clinical safety net that ensures appropriate patient selection.
The Role of Physician Oversight in Telehealth ED Treatment
The shift toward telehealth ED treatment has made physician-supervised PDE5 inhibitor prescribing more accessible, but access and quality are not synonymous. The most important variable in outcomes is whether a real licensed physician evaluates the patient, reviews their health history and current medications, and selects the appropriate agent and dose.
OnyxMD operates as a physician-supervised telehealth platform. US-licensed physicians review every intake, prescriptions are filled through an FDA-registered, HIPAA-compliant pharmacy, and patients receive ongoing clinical access, not just a transaction. If you want to understand the clinical reasoning behind formulation choices, the OnyxMD blog covers these topics in depth.
Conclusion
Daily tadalafil 5mg is one of the better-studied pharmacological approaches to erectile dysfunction available today. The clinical evidence supports its efficacy, its safety profile, and, increasingly, its potential role in broader vascular health. Chewable formulations offer equivalent systemic exposure with added convenience, and combination approaches with vardenafil may offer complementary pharmacokinetic benefits for appropriate patients.
Treating ED is not just about a single encounter. It's about restoring confidence, supporting vascular health, and removing a source of chronic psychological stress. The evidence base for daily tadalafil increasingly supports that framing.
If you're ready to explore clinically-formulated options, OnyxMD offers physician-supervised treatment plans starting with a free online assessment at intake.getonyxmd.com.
These statements have not been evaluated by the FDA. This content is for informational purposes only and does not constitute medical advice. Consult a licensed physician before starting any medication.
References
Motawi AT, GamalEl Din SF, Meatmed EM, Fahmy I. "Evaluation of efficacy and safety profile of tadalafil 5 mg daily dose in the tablet form versus oral dispersible film in men with mild-to-moderate erectile dysfunction." International Urology and Nephrology. 2024;56:2531–2537. doi:10.1007/s11255-024-04003-x PMID: 38433177
Jehle DVK, Sunesra R, Uddin H, Paul KK, et al. "Benefits of Tadalafil and Sildenafil on Mortality, Cardiovascular Disease, and Dementia." The American Journal of Medicine. 2024;S0002-9343(24)00705-8. doi:10.1016/j.amjmed.2024.10.022 PMID: 39532245
Kloner RA, Stanek E, Desai K, et al. "The association of tadalafil exposure with lower rates of major adverse cardiovascular events and mortality in a general population of men with erectile dysfunction." Clinical Cardiology. 2024;47:e24234. doi:10.1002/clc.24234 PMID: 38377018
Fahmy G, Hess J. "Tadalafil." In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025. PubMed NBK603743
Medical Disclaimer: The information provided on this website is for educational and informational purposes only and is not intended as medical advice. OnyxMD services should not be used to diagnose, treat, cure, or prevent any disease or medical condition. Always consult with a qualified healthcare provider before beginning any supplement regimen or health program.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
Individual Results: Results may vary. The experiences and testimonials presented on this website are individual results that may not be typical. Your experience may be different.
Telehealth Services: OnyxMD provides telehealth services in 47 states (excluding AK, MS, NJ) through licensed healthcare providers via our partner Beluga Health, P.A. Services are subject to clinical evaluation and may not be appropriate for all individuals. Prescriptions fulfilled by Strive Pharmacy LLC (License #99-9817) and EPIQ SCRIPTS LLC.